Explanipedia

#728 Predicting individual patient response to corticosteroids in IgA nephropathy: a secondary analysis from the TESTING cohort Open

Mark Canney, Sana Shan, Lee Er, Laurent Billot, Jialin Han , et al. · 2025

Background and Aims Corticosteroids are an effective treatment for IgA nephropathy but are associated with considerable adverse events. The TESTING clinical trial showed an average treatment effect of a 47% relative risk reduction in the p…

Sex Differences Across Corticosteroid Response and Outcomes in IgA Nephropathy Open

Dana Kim, Mark Woodward, Jicheng Lv, Michelle Hladunewich, Vivekanand Jha , et al. · 2025

Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular Disease Open

Jill Krissberg, Michelle M. O’Shaughnessy, Abigail R. Smith, Margaret Helmuth, Salem Almaani , et al. · 2025

Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts Open

Sean J. Barbour, Rosanna Coppo, Jonathan Barratt, Lee Er, Richard Lafayette , et al. · 2025

Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy Open

Sean J. Barbour, Rosanna Coppo, Lee Er, María Luisa Russo, Zhihong Liu , et al. · 2024

The pediatric International IgA Nephropathy (IgAN) Prediction Tool comprises two models with and without ethnicity and is the first method to predict the risk of a 30% decline in estimated glomerular filtration rate (eGFR) or kidney failur…

The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy Open

Dana Kim, Jicheng Lv, Michelle Hladunewich, Vivekanand Jha, Lai Seong Hooi , et al. · 2024

Reduced-dose methylprednisolone is effective in improving kidney outcomes in high risk IgAN; however, it is associated with a modestly higher number of SAEs compared to placebo.

Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial Open

Jonathan Barratt, Adrian Liew, See Cheng Yeo, Anders Fernström, Sean J. Barbour , et al. · 2024

Background IgA nephropathy is the most common primary GN. Clinical features of IgA nephropathy include proteinuria, which is the strongest known surrogate of progression to kidney failure. Complement pathway activation is a critical driver…

Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification Open

Sanjeev Sethi, Laurence H. Beck, Richard J. Glassock, Mark Haas, An S. De Vriese , et al. · 2023

Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification Open

Sanjeev Sethi, Laurence H. Beck, Richard J. Glassock, Mark Haas, An S. De Vriese , et al. · 2023

Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy Open

Sean J. Barbour, Fernando C. Fervenza, Dilshani Induruwage, Paul Brenchley, Brad H. Rovin , et al. · 2023

Background The 2021 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend following anti-phospholipase A2 receptor (PLA2R) antibody levels as a marker of treatment response in membranous nephropathy; however, the optimal ti…

Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy Open

Krzysztof Kiryluk, Elena Sánchez, Shufeng Zhou, Francesca Zanoni, Lili Liu , et al. · 2023

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy Open

Jonathan Barratt, Richard Lafayette, Jens Kristensen, Andrew Stone, Daniel Cattran , et al. · 2022

Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular Disease Open

Jill Krissberg, Michelle M. O’Shaughnessy, Abigail R. Smith, Margaret Helmuth, Salem Almaani , et al. · 2022

Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy Open

Sean J. Barbour, Rosanna Coppo, Hong Zhang, Zhihong Liu, Yusuke Suzuki , et al. · 2022

Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses Open

Elissa G. Currie, Bryan Coburn, Elisa A. Porfilio, Ping Lam, Olga L. Rojas , et al. · 2022

IgA nephropathy (IgAN) is a leading cause of kidney failure, yet little is known about the immunopathogenesis of this disease. IgAN is characterized by deposition of IgA in the kidney glomeruli, but the source and stimulus for IgA producti…

GWAS defines pathogenic signaling pathways and prioritizes drug targets for IgA nephropathy Open

Krzysztof Kiryluk, Elena Sánchez, Shufeng Zhou, Francesca Zanoni, Lili Liu , et al. · 2021

IgA nephropathy (IgAN) is a progressive form of kidney disease defined by glomerular deposition of IgA. We performed a genome-wide association study involving 10,146 kidney biopsy-diagnosed IgAN cases and 28,751 matched controls across 17 …

Editorial Board Open